Rosuvastatin Dose 1

Preclinical

AstraZeneca

Rosuvastatin Dose 1 is one of 3 therapeutic programs targeting Dyslipidaemia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

DyslipidaemiaActive, not recruiting

DyslipidaemiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Dyslipidaemia

#DrugCompanyPhaseTrials

Crestor

AstraZeneca

Phase 2

3 2

AZD0780

AstraZeneca

Phase 2

2 3

Rosuvastatin Dose 1

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

PreclinicalActive, not recruiting

Dyslipidaemia

NCT06834932

Clinical

Trials by Indication[1]

Dyslipidaemia1 trial

A Randomised, Double-blind, Placebo-controlled, Multi-centre, Sequential Phase II, and Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 Administered for up to 52 Weeks in Participants With Dyslipidaemia (AZURE-CHINA)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Preclinical·NCT06834932·432 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Rosuvastatin Dose 1. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Rosuvastatin Dose 1. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: AstraZeneca

Rosuvastatin Dose 1

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Dyslipidaemia1 trial

References

Drug Info

Quick Facts

Related News